Original Article

Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity

Correspondence to: G. F. Watts

We examined the effect of genetic polymorphisms of proteins regulating intrahepatic processing of apolipoprotein B-100 (apoB) and the supply of neutral lipids to the liver on the hepatic secretion of very low density lipoprotein (VLDL) apoB in obesity. Hepatic secretion of very low density apolipoprotein B-100 (VLDL apoB) was measured using an infusion of [1-¹³C]leucine in 29 obese men. Isotopic enrichment and turnover of VLDL apoB was determined using gas chromatography–mass spectrometry and multi-compartmental modelling, respectively. Visceral fat was measured by magnetic resonance imaging. Genotypes for the apoB signal peptide (SP27/SP24 alleles), microsomal triglyceride transfer protein promoter (MTP, -493 G/T alleles), apoE (E2, E3, E4 alleles), hepatic lipase promoter (-514 C/T alleles), and cholesteryl ester transfer protein (CETP, Taq1B B1/B2 alleles) were determined using polymerase chain reaction. Statistically significant associations were found between hepatic secretion of apoB and allelic combinations of i) apoB SP with apoE (P = 0.02), hepatic lipase (P = 0.02), and CETP (P = 0.006) genes, ii) MTP promoter with CETP genes (P = 0.03); the association with apoBSP/MTP promoter allelic combinations just failed to reach significance (P = 0.06), however. The CETP/apoBSP allelic combination was the most significant predictor of apoB secretion, and this was independent of visceral fat, plasma lathosterol and insulin levels, and dietary fat. SP24 carriers who were homozygous for CETP B1 had 60% lower apoB secretion than B2 heterozygotes who were non-carriers of SP24 (10.5 ± 1.74 mg/kg fat free mass/day, n = 7 vs. 26.1 ± 3.16, n = 22).

The data suggest that variation in both the apoB and CETP genes may be a major genetic determinant of the hepatic secretion of apoB in men with visceral obesity.—Watts, G. F., F. M. Riches, S. E. Humphries, P. J. Talmud, and F. M. Bockxmeer. Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. J. Lipid Res. 2000. 41: 481;–488.

Supplementary key words: genotypes, apoB, signal peptide, cholesterol ester transfer protein, apoB-100, obesity, stable isotope

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. C. Chan, M. N. Nguyen, G. F. Watts, and P. H. R. Barrett Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 557 - 564. [Abstract] [Full Text] [PDF]

				B. Lundahl, C. Skoglund-Andersson, M. Caslake, D. Bedford, P. Stewart, A. Hamsten, C. J. Packard, and F. Karpe Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E739 - E745. [Abstract] [Full Text] [PDF]

				T. W.K. Ng, G. F. Watts, M. S. Farvid, D. C. Chan, and P. H. R. Barrett Adipocytokines and VLDL Metabolism: Independent Regulatory Effects of Adiponectin, Insulin Resistance, and Fat Compartments on VLDL Apolipoprotein B-100 Kinetics? Diabetes, March 1, 2005; 54(3): 795 - 802. [Abstract] [Full Text] [PDF]

				D.C. Chan, G.F. Watts, P.H.R. Barrett, A.J. Whitfield, and F.M. van Bockxmeer ATP-Binding Cassette Transporter G8 Gene As a Determinant of Apolipoprotein B-100 Kinetics in Overweight Men Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2188 - 2191. [Abstract] [Full Text] [PDF]

				S. M. Boekholdt and J. F. Thompson Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease J. Lipid Res., July 1, 2003; 44(6): 1080 - 1093. [Abstract] [Full Text] [PDF]

				O. Tschritter, A. Fritsche, F. Shirkavand, F. Machicao, H. Haring, and M. Stumvoll Assessing the Shape of the Glucose Curve During an Oral Glucose Tolerance Test Diabetes Care, April 1, 2003; 26(4): 1026 - 1033. [Abstract] [Full Text] [PDF]

				D. C Chan, G. F Watts, T. A Mori, P H. R Barrett, T. G Redgrave, and L. J Beilin Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity Am. J. Clinical Nutrition, February 1, 2003; 77(2): 300 - 307. [Abstract] [Full Text] [PDF]

				A. Carpentier, B. W. Patterson, N. Leung, and G. F. Lewis Sensitivity to Acute Insulin-Mediated Suppression of Plasma Free Fatty Acids Is Not a Determinant of Fasting VLDL Triglyceride Secretion in Healthy Humans Diabetes, June 1, 2002; 51(6): 1867 - 1875. [Abstract] [Full Text] [PDF]

				D. C. Chan, G. F. Watts, P. H. R. Barrett, T. A. Mori, L. J. Beilin, and T. G. Redgrave Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral Obesity J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2283 - 2289. [Abstract] [Full Text] [PDF]

				M. Lambert, L. Assouline, J. C. Feoli-Fonseca, N. Brun, E. E. Delvin, and E. Levy Determinants of Lipid Level Variability in French-Canadian Children With Familial Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 979 - 984. [Abstract] [Full Text] [PDF]

				B. Agerholm-Larsen, A. Tybjarg-Hansen, P. Schnohr, R. Steffensen, and B. G. Nordestgaard Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease : The Copenhagen City Heart Study Circulation, October 31, 2000; 102(18): 2197 - 2203. [Abstract] [Full Text] [PDF]